Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 18th Nov 2013 08:10

AGA Rangemaster: N+1 Singer raises its target price from 150p to 175p and keeps a buy recommendation.APR Energy: Jefferies cuts target price from 1300p to 1260p retaining a buy recommendation.Atkins (WS): LIberum Capital increases target price from 1300p to 1400p maintaining a buy recommendation.Aveva: Panmure Gordon ups target price from 2374p to 2386p and keeps a hold recommendation.Bank of Georgia: Panmure Gordon raises target price from 2200p to 3000p and retains a buy recommendation.Big Yellow Group: Numis raises target price from 460p to 535p keeping an add rating.Cairn Energy: UBS moves target price from 310p to 305p and stays with its buy recommendation.Cape: JP Morgan lowers target price from 299p to 288p and maintains a neutral rating.Carr's Milling: Investec increases target price from 1710p to 1900p and maintains a buy recommendation.Diploma: Jefferies takes target price from 720p to 750p and reiterates a buy recommendation. Numis downgrades from add to hold with a target price of 697p.Drax Group: Liberum Capital raises target price from 640p to 735p upgrading to buy.Euromoney: Investec ups target price from 1200p to 1250p and reiterates a buy recommendation.Foxtons: Canaccord Genuity upgrades to buy woth a target price of 320p.Gem Diamonds: JP Morgan moves target price from 180p to 185p retaining an overweight rating.International Consolidated Airlines Group: Nomura takes target price from 335p to 380p and keeps a buy recommendation.ITE Group: Investec places its target price (prev.: 335p) under review, while keeping its buy recommendation.Lancashire Holdings: Numis raises target price from 865p to 935p and upgrades from hold to add.Lonmin: Investec ups target price from 266p to 287p, but still recommends selling.Majestic Wine: Investec raises target price from 495p to 620p and retains a buy recommendation. Panmure Gordon increases target price from 500p to 635p and stays with its buy recommendation.MITIE Group: Investec ups target price from 310p to 330p and keeps a buy recommendation.New World Resources: Jefferies shifts target price from 70p to 75p and maintains its hold recommendation.Northern Petroleum: Westhouse Securities shifts target price from 123p to 120p, while upgrading to buy.Ocean Wilson Holdings: Cantor Fitzgerald ups target price from 1345p to 1400p and stays with its buy recommendation.Ophir Energy: Canaccord Genuity ups target price from 375p to 400p and retains a hold recommendation.Partnership Assurance: Deutsche Bank reduces target price from 470p to 385p keeping a hold recommendation.SAB Miller: JP Morgan increases target price from 3270p to 3465p and leaves its overweight rating unchanged.Shire: Jefferies raises target price from 3100p to 3400p and keeps a buy recommendation.Summit Corporation: N+1 Singer moves target price from 11p to 16.3p and reiterates a buy recommendation.Ultra Electronics: UBS cuts target price from 1900p to 1820p maintaining a neutral rating. JP Morgan reduces target price from 2100p to 1920p leaving its neutral rating unaltered.Vedanta Resources: Deutsche Bank cuts target price from 1050p to 1020p retaining a hold recommendation. Credit Suisse reduces target price from 1350p to 1270p and leaves its outperform rating unaltered.Volex Group: FinnCap upgrades to hold with a target price of 90p.
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.